Table 3.

Comparison between different studied groups as regards clinical and laboratory data

		G1 (35)	G2 (6)	G3 (9)	G4 (27)	Total (77)	P value
Male/Female		20/15	4/2	7/2	12/15	43/34	0.32
Median age of onset (yrs) (Range)		10 (6-15)	12 (10-14)	11 (9-18)	8 (1-17)	10 (1-18)	0.017 *
Duration between onset and diagnosis (yrs)		0.83 ± 3	4.75 ± 0.9	1.9 ± 0.6	-	1.03 ± 0.2	0.000*
Duration of follow up (ms) Mean (Range)		60.27 (0.25-156)	32.5 (12-48)	75.86 (12-156)	89.55 (5-156)	58.9 (0.25-156)
S. Ceruloplasmin	<7	25 (71.4)	6 (100)	7 (77.8)	19 (70.4)	57 (74)
(mg%)	7-20	6 (17.1)	0 (0)	2 (22.2)	7 (25.9)	15 (19.5)
No. (%)	>20	4 (11.4)	0 (0)	0 (0)	1 (3.7)	5 (6.5)
	Hepatomegaly	22 (62.9)	2 (33.3)	5 (55.6)	22 (81.5)	51 (66.2)	0.134
Hepatic	Splenomegaly	22 (62.9)	1 (16.6)	6 (66.6)	9 (33.3)	38 (49.4)	0.006
signs	Jaundice	24 (68.6)	0 (0)	2 (22.2)	0 (0)	26 (33.8)	0.000*
No. (%)	Ascites	17 (48.6)	0 (0)	4 (44.4)	0 (0)	21 (27.3)	0.000*
	LL Oedema	15(42.9)	0 (0)	5(55.6)	0 (0)	20 (26)	0.000*
	Encephalopathy	2 (5.7)	0 (0)	0 (0)	0 (0)	2 (2.6)
	ALT (x ULN)	2.8 ± 0.4	1.7 ± 0.8	1.7 ± 0.3	3.2 ± 0.5	2.7 ± 0.3	0.056
Liver	AST (x ULN)	3.9 ± 0.5	1.0	3.9 ± 0.2	2.4 ± 0.3	3.2 ± 0.3	0.001*
function	Bilirubin (mg%)	8.0 ± 1.7	2.5 ± 1.6	1.8 ± 0.5	0.8 ± 0.1	4.2 ± 0.8	0.000*
tests Mean ± SD	INR	3.0 ± 0.4	1.3 ± 0.2	3.8 ± 0.2	1.1 ± 0.04	2.3 ± 3.4	0.000*
	Albumin (gm%)	2.6 ± 0.1	4.3 ± 0.1	3.0 ± 0.3	3.9 ± 0.2	3.2 ± 1.2	0.000*
	Chronic hepatitis	4/11 (36.4)	1/4 (25)	0/4 (0)	7/20 (35)	12/39 (30.8)
Liver	Cirrhosis	7/11 (63.6)	1/4 (25)	4/4 (100)	9/20 (45)	21/39 (53.8)
biopsy	Steatosis	3/11 (27.3)	1/4 (25)	2/4 (50)	2/20 (10)	8/39 (20.5)
No. (%)	Glycogenated nuclei	2/11 (18.2)	1/4 (25)	0/4 (0)	7 (35)	10/39 (25.6)
	Cu associated protein	4/11 (36.4)	0/4 (0)	1/4 (25)	5 (25)	10/39 (25.6)
	Pigment	1/11 (9)	1/4 (25)	0/4 (0)	2 (10)	4/39 (10.3)
Positive KF rings No. (%)		27/28 (96.4)	6/6 (100)	8/8 (100)	4/23 (17.4)	45/65 (69.2)	0.000